Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS).

Abstract

PURPOSE\nThe role of chemotherapy has not been established in the treatment of metastatic squamous cell oesophageal cancer (mESCC).\n\n\nPATIENTS AND METHODS\nE-DIS is a discontinuation trial, aimed at estimating efficacy, quality of life and safety of chemotherapy continuation (CT-CONT) in patients with mESCC who are free from progression after a selection phase of chemotherapy. The primary end-point was overall survival.\n\n\nRESULTS\nSixty-seven patients were randomised. The 9-month survival rate was 50% (85% confidence interval [CI]: 37-62%) and 48% (85% CI: 35-60%) in the CT-CONT arm and in the chemotherapy discontinuation (CT-DISC) arm, respectively. The time until definitive deterioration of the global health status (European Organisation for Research and Treatment of Cancer [EORTC] core quality of life questionnaire) was 6.6 months (95% CI: 3.3-12.4) for the CT-CONT arm and 4.2 months (95% CI: 2.9-6.3) for the CT-DISC arm, with a hazard ratio (HRCT-DISC/CT-CONT)\xa0=\xa01.44 (95% CI: 0.82-2.53). We observed a beneficial trend in favour of CT-CONT (HR\xa0>\xa01) for most dimensions, including an improvement for three dimensions (dysphagia, eating\xa0and oesophageal pain) of the EORTC Oesophageal Cancer Module QLQ-OES18.\n\n\nCONCLUSION\nCT-CONT provides an overall survival rate that is similar to CT-DISC. E-DIS trial provides valuable data to support shared decision-making between physicians and patients regarding CT-CONT/DISC.